Saturday, March 21, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Israel Is Offering Its Older Citizens A 3rd COVID-19 Shot As Infections Rise

Israel’s prime minister on Thursday announced that the country would offer a coronavirus booster to people over 60 who have already been vaccinated.

The announcement by Naftali Bennett makes Israel, which launched one of the world’s most successful vaccination drives early this year, the first country to offer a third dose of a Western vaccine to its citizens on a wide scale.

“I’m announcing this evening the beginning of the campaign to receive the booster vaccine, the third vaccine,” Bennett said in a nationally televised address. “Reality proves the vaccines are safe. Reality also proves the vaccines protect against severe morbidity and death. And like the flu vaccine that needs to be renewed from time to time, it is the same in this case.”

The decision comes at a time of rising infections and signs that the vaccine’s efficacy dwindles over time.

Source: NPR

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!